title: Effects of platelet-activating factor antagonist E5880 on intrahepatic and systemic metabolic responses to transient hepatic inflow occlusion and reperfusion in the rabbit.
abstract: We investigated the effects of pretreatment with a potent platelet-activating factor (PAF) receptor antagonist (E5880) on the changes in hepatic and systemic metabolism induced by transient hepatic ischemia and reperfusion. Sixty-five rabbits were assigned to four groups that either did or did not undergo a period of hepatic ischemia and reperfusion with or without pretreatment. E5880 was administered intraportally 1 minute prior to inflow occlusion. Twenty minutes of warm ischemia was followed by 30 minutes of reperfusion. Blood gas analyses and measurements of levels of arterial pyruvate, lactate, and ketone bodies, arterial and portal ammonia and endotoxin, and intrahepatic adenine nucleotide, pyruvate, and lactate were performed. Results were analyzed by either ANOVA or chi-square analysis. Hepatic tissue ATP and energy charge levels were significantly increased and the AMP level was significantly decreased after 30 minutes of reperfusion in the pretreatment group compared to those without pretreatment. At the same time, parameters reflecting hepatic mitochondrial function, such as the arterial ketone body ratio and arterial ammonia level, improved, although they were not statistically significant. No difference was observed for parameters reflecting systemic changes, such as arterial blood gas values and pyruvate and lactate levels. PAF is thought to mediate metabolic changes after hepatic ischemia and reperfusion. PAF released in the liver may exert local effects, which appear to be attenuated by pretreatment with E5880. Systemic metabolic changes seen after hepatic ischemia and reperfusion may be mediated by factors other than PAF.
authors.affiliation: Trauma and Critical Center, Teikyo University School of Medicine, 11-1, Kaga 2-chome, Itabashi, Tokyo 173, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakatani
authors.forename: Y
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: H
authors.initials: H
authors.lastname: Ando
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000227:Adenine Nucleotides / Q000097:blood; D000641:Ammonia / Q000097:blood; D000704:Analysis of Variance; D000818:Animals; D001784:Blood Gas Analysis; D001786:Blood Glucose / Q000032:analysis; D004734:Energy Metabolism / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000097:blood; D008099:Liver / Q000098:blood supply* / Q000187:drug effects; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D019289:Pyruvic Acid / Q000097:blood; D011817:Rabbits; D015427:Reperfusion Injury / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D000227:Adenine Nucleotides; D001786:Blood Glucose; D010880:Piperidines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C072429:E 5880; D019344:Lactic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000641:Ammonia; D019289:Pyruvic Acid